Reviews/Perioperative Immunotherapy Solid Tumours/Adjuvant nivolumab disease-free survival in bladder cancer
Bladder · PERIO-BLAD-01 · v2
One large, well-designed randomised trial tested nivolumab given after surgery against a placebo in people with high-risk urothelial cancer, and it clearly delayed cancer coming back [13]. The same trial was reported several more times as patients were followed for longer, and the result held up each time and across different patient groups [3][7][6]. When the panel looked only at patients whose cancer was in the bladder, the group the claim is about, the benefit was still there [9][11]. Smaller real-world records of patients treated in ordinary practice pointed the same way [8][10]. The main limitation the panel kept returning to is that all the strong evidence comes from this one trial, with no separate study to confirm it.
The corpus demonstrates a disease-free survival benefit for adjuvant nivolumab versus placebo in the intent-to-treat population: hazard ratio 0.70 with P<0.001 [13], carried forward at 36.1-month follow-up (HR 0.71) [3][7] and across PD-L1 strata [6]. In the muscle-invasive bladder cancer subgroup (the population most closely matching 'following radical cystectomy') the benefit persisted regardless of PD-L1 status, HR 0.63 [9][11]. Real-world cohorts report concordant disease-free survival rates [8][10]. Every read-out that bears directly on the claim at highest relevance, however, is a report of the same trial, CheckMate 274. The contested point: The division is not over direction but over independence and clinical meaning: all pivotal data derive from one trial, and the exact 'following radical cystectomy' population rests on an exploratory subgroup [9][11] rather than a primary analysis. Overall survival matured only later in the intent-to-treat population (HR 0.76) [3], and the bladder-subgroup OS significance boundaries were not crossed [11].
All 29 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
All seven relevance-5 sources are the same trial, CheckMate 274 (NCT02632409). The corpus contains one pivotal RCT reported repeatedly; there is no independent confirmatory adjuvant-nivolumab RCT. The apparent depth is a single data source.
The claim specifies 'following radical cystectomy', but CheckMate 274 enrolled bladder, ureter and renal pelvis MIUC after radical surgery (upper-tract disease is treated by nephroureterectomy, not cystectomy). The exact post-cystectomy match rests on the MIBC subgroup [9][11], which is an exploratory, not primary, analysis.
Where it remains uncertain. Every high-relevance source is the same trial, and the post-cystectomy match relies on the exploratory bladder subgroup [9][11] while overall survival is less mature [3][11].
Aleatory
Overall-survival events are still accruing; bladder-subgroup OS boundaries were not crossed at analysis [11] and ITT OS reached significance only at later follow-up [3].
Epistemic
All high-relevance evidence is CheckMate 274 [13][3][7][6][9][11]; no independent confirmatory adjuvant-nivolumab RCT exists in the corpus.
Inferential
The claim is scoped to disease-free survival, but reading lasting clinical benefit into it requires an inferential step to overall survival that the corpus only partly supports [3][11].
The load-bearing papers from a corpus of 29, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Durability of DFS benefit at 36.1-month follow-up.
“Consistent DFS benefit with nivolumab versus placebo was observed in both the ITT (hazard ratio [HR], 0.71 [95% CI, 0.58 to 0.86]) and PD-L1 ≥1% (HR, 0.52 [95% CI, 0.37 to 0.72]) patients.”
Panel auditInternal validity: high · scope of inference: High-risk MIUC (bladder, ureter, renal pelvis) after radical resection, extended 36.1-month follow-up.Key limitations: mixed urothelial sites not bladder only · update report of a prior trial
Confirms DFS benefit across PD-L1 biomarker strata.
“DFS was improved with nivolumab versus placebo for patients with TC ≥1% (hazard ratio [HR] 0.50, 95% confidence interval [CI] 0.35-0.71)”
Panel auditInternal validity: high · scope of inference: High-risk MIUC after radical surgery, DFS stratified by PD-L1 TC and CPS.Key limitations: retrospective CPS scoring · biomarker subgroup analysis · mixed urothelial sites
Extended follow-up confirms sustained median DFS separation.
“median DFS was 22.0 months with NIVO versus 10.9 months with PBO in ITT patients”
Panel auditInternal validity: high · scope of inference: High-risk MIUC after radical resection, 36.1-month median follow-up.Key limitations: conference abstract · p values not in abstract · mixed urothelial sites
Only pooled recurrence and survival rates are given with no formal comparative analysis, as the authors state.
Panel auditInternal validity: low · scope of inference: Real-world perioperative management of MIUC in Spain.Key limitations: no comparative analysis · mixed treatment patterns · observational
4 of 29 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
One large, rigorous, positive registration RCT directly meeting the DFS endpoint, consistent across every analysis and supported by real-world data, warrants Established, held just below the ceiling because all pivotal evidence derives from a single trial.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent confirmatory RCT. All pivotal evidence is CheckMate 274 [13]; replication would separate a true effect from single-trial features. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An independent randomised, placebo- or standard-of-care-controlled trial of adjuvant nivolumab in high-risk MIUC after radical surgery.
Open question: Would the disease-free survival benefit of adjuvant nivolumab replicate in a trial independent of CheckMate 274? Why it is still open: Every high-relevance source in the corpus is CheckMate 274 [13][3][7][9][11]; no independent RCT is present.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19